Investigating how lipid signaling affects liver cancer development in patients with fatty liver disease
A lipid signaling network through stearoyl Co-A desaturase regulates hepatocellular carcinogenesis through YAP/TAZ activity
This study is looking at how liver cancer can develop in people with nonalcoholic fatty liver disease and aims to find out how certain fats in the body might affect cancer growth, so we can discover better ways to prevent and treat liver cancer for those at higher risk.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Greater Los Angeles Healthcare System NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10693580 on NIH RePORTER |
What this research studies
This research focuses on understanding the mechanisms behind liver cancer development in patients with nonalcoholic fatty liver disease (NAFLD). It aims to explore how lipid signaling pathways, particularly involving the enzyme stearoyl-CoA desaturase, influence the activity of key proteins that drive cancer progression. By analyzing liver tissue samples from patients undergoing bariatric surgery, the study seeks to identify potential early treatment strategies and preventive measures for those at high risk of liver cancer. The findings could lead to improved screening and management of liver cancer in this vulnerable population.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with nonalcoholic fatty liver disease who are at high risk for developing liver cancer.
Not a fit: Patients without nonalcoholic fatty liver disease or those with other unrelated liver conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better prevention and treatment strategies for liver cancer in patients with fatty liver disease.
How similar studies have performed: Previous research has shown that targeting lipid signaling pathways can reduce liver cancer incidence, indicating a promising area of investigation.
Where this research is happening
Los Angeles, United States
- VA Greater Los Angeles Healthcare System — Los Angeles, United States (Active)
Researchers
- Principal investigator: Benhammou, Jihane — VA Greater Los Angeles Healthcare System
- Study coordinator: Benhammou, Jihane
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.